ES2176456T3 - Procedimiento de preparacion de un compuesto inhibidor del vih proteasa. - Google Patents

Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.

Info

Publication number
ES2176456T3
ES2176456T3 ES96915755T ES96915755T ES2176456T3 ES 2176456 T3 ES2176456 T3 ES 2176456T3 ES 96915755 T ES96915755 T ES 96915755T ES 96915755 T ES96915755 T ES 96915755T ES 2176456 T3 ES2176456 T3 ES 2176456T3
Authority
ES
Spain
Prior art keywords
preparation
proteasa
hiv
procedure
inhibiting compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96915755T
Other languages
English (en)
Inventor
Jien-Heh Tien
Jerome A Menzia
Arthur J Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2176456T3 publication Critical patent/ES2176456T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE DESCUBREN PROCESOS PARA LA PREPARACION DE (2S,3S,5S) 5 (N IL)AMINO)CARBONIL) L)METOXICARBONIL)AMINO) SAL DE ADICION DE ACIDO DEL MISMO Y (2S,3S,5S) CARBONIL) CARBONIL)AMINO) ADICION DE ACIDO DEL MISMO.
ES96915755T 1995-06-06 1996-05-13 Procedimiento de preparacion de un compuesto inhibidor del vih proteasa. Expired - Lifetime ES2176456T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/469,965 US5567823A (en) 1995-06-06 1995-06-06 Process for the preparation of an HIV protease inhibiting compound

Publications (1)

Publication Number Publication Date
ES2176456T3 true ES2176456T3 (es) 2002-12-01

Family

ID=23865732

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96915755T Expired - Lifetime ES2176456T3 (es) 1995-06-06 1996-05-13 Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.

Country Status (11)

Country Link
US (1) US5567823A (es)
EP (1) EP0830353B1 (es)
JP (2) JP4580044B2 (es)
AT (1) ATE216696T1 (es)
CA (1) CA2219983C (es)
DE (1) DE69620882T2 (es)
DK (1) DK0830353T3 (es)
ES (1) ES2176456T3 (es)
MX (1) MX9709454A (es)
PT (1) PT830353E (es)
WO (1) WO1996039398A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100187990B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6180634B1 (en) * 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6803466B1 (en) * 1997-12-08 2004-10-12 The Scripps Research Institute HIV/FIV protease inhibitors having a small P3 residue
AU1904599A (en) * 1997-12-08 1999-06-28 Scripps Research Institute, The Hiv/fiv protease inhibitors having a small p3 residue
CO5090830A1 (es) * 1998-07-20 2001-10-30 Abbott Lab Poliformo de un agente farmaceutico
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
DK1733725T4 (da) * 1999-06-04 2012-09-17 Abbott Lab Farmaceutiske formuleringer omfattende mindst én HIV-proteaseinhiberende forbindelse
IT1313624B1 (it) * 1999-09-21 2002-09-09 Archimica Spa Ora Clariant Lif Procedimento per la sintesi del ritonavir
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
BR0011864A (pt) 2000-01-19 2004-07-20 Abbott Lab Formulações farmacêuticas
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) * 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
AP2702A (en) 2005-12-30 2013-07-23 Gilead Sciences Inc Methods for improving the pharmacokinetics of HIV integrase inhibitors
PT2049506E (pt) * 2006-07-07 2015-10-09 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
ES2555209T3 (es) * 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
CN101967130B (zh) * 2010-07-02 2012-12-26 厦门市亨瑞生化有限公司 利托那韦中间体的合成方法
CN102786494B (zh) * 2012-07-26 2016-01-06 合肥华方医药科技有限公司 利托那韦异构体杂质的合成研究及控制方法
WO2015125082A1 (en) * 2014-02-21 2015-08-27 Mylan Laboratories Limited Improved process for the preparation of ritonavir
CN104311503B (zh) * 2014-11-03 2017-01-25 东北制药集团股份有限公司 一种制备抗hiv药物利托那韦的方法
CN111646953A (zh) * 2020-04-23 2020-09-11 厦门蔚嘉制药有限公司 一种合成利托那韦的新方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
KR100187990B1 (ko) * 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체

Also Published As

Publication number Publication date
DE69620882T2 (de) 2002-12-12
ATE216696T1 (de) 2002-05-15
US5567823A (en) 1996-10-22
JP4580044B2 (ja) 2010-11-10
PT830353E (pt) 2002-10-31
JP2010270123A (ja) 2010-12-02
CA2219983A1 (en) 1996-12-12
CA2219983C (en) 2007-09-18
JP5390477B2 (ja) 2014-01-15
WO1996039398A1 (en) 1996-12-12
DK0830353T3 (da) 2002-07-29
DE69620882D1 (de) 2002-05-29
MX9709454A (es) 1998-02-28
EP0830353A1 (en) 1998-03-25
JPH11507029A (ja) 1999-06-22
EP0830353B1 (en) 2002-04-24

Similar Documents

Publication Publication Date Title
ES2176456T3 (es) Procedimiento de preparacion de un compuesto inhibidor del vih proteasa.
ES2124373T3 (es) Procedimiento para la preparacion de derivados del acido n-acil-n,n',n'-etilendiamintriacetico.
DE3378052D1 (en) Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
TR199700844T1 (xx) Pirazolil-Benzoil T�revleri.
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
TR200800474T2 (tr) Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
AU2733997A (en) N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
ES2070660B1 (es) Un procedimiento para la preparacion de 2,5-damino-3-hidroxihexanos sustituidos, utiles como inhibidores de proteasas retrovirales.
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
RU95106362A (ru) Производные липопептида, способ их получения, содержащая их фармацевтическая композиция и способ ее получения
ES8502105A1 (es) Un procedimiento para la preparacion de derivados de diben- zopirano
AU7249198A (en) Substantially pure zonulin, a physiological modulator of mammalian tight junctions
BG101893A (en) Nodulosporic acid derivatives
BR9714650A (pt) " derivados farmacêuticos de ácido aminofosfÈnico "
HUP9900935A2 (hu) Baktériumellenes és gombaellenes hatású peptid és eljárás az előállítására
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
ATE270667T1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
AU4765396A (en) Method of preparing retroviral protease inhibitor intermediates
ES8601908A1 (es) Procedimiento para la preparacion de nuevas 5,11-dihidro-6h-dibenzo (b,e)azepin-6-onas sustituidas
ES2125463T3 (es) Procedimiento para la preparacion de derivados de acido n-acetil neuraminico.
HUT55054A (en) Process for producing new antibioticum mersadicin and salts and pharmaceutical compositions containing them as active components
ES2099820T3 (es) Procedimiento para la preparacion de trans-piperidina-2,5-dicarboxilatos.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
BR9807785A (pt) Processo para a preparação do composto, e, composto